Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.65% | 9.63% | -8.05% | -9.52% | -51.49% |
| Total Depreciation and Amortization | 16.34% | 10.42% | -1.06% | -0.19% | -2.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 344.62% | 6.10% | -102.35% | -132.68% | -65.93% |
| Change in Net Operating Assets | -209.99% | -226.40% | -221.60% | 1,363.61% | 679.67% |
| Cash from Operations | -33.87% | -44.64% | -56.17% | -44.92% | -35.92% |
| Capital Expenditure | -269.49% | -41.96% | -15.42% | 38.23% | 70.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -229.26% | -2.45% | -100.49% | -100.29% | -100.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14,053.50% | -11,387.66% | -9,050.65% | -3,499.21% | 61.86% |
| Issuance of Common Stock | -27.10% | 159.57% | 4.35% | 565.10% | 201.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.65% | 117.28% | -36.46% | 500.06% | 279.20% |
| Foreign Exchange rate Adjustments | -543.33% | -338.01% | 113.24% | 16.69% | 180.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.46% | 1,175.93% | -184.82% | 105.68% | 419.67% |